ArticleJournal of immunology (Baltimore, Md. : 1950)2018
Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses.
Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Peptide nanofibers and PAMP agonist combinations enhance pulmonary CD4Journal of nanobiotechnology · 2026Article
- Carbohydrate fatty acid monosulphate ester adjuvant enhances the immunogenicity of influenza antigensFrontiers in immunology · 2026Article
- Lipid A mimetic BECC438 potentiates durable and balanced antibody responses in an ovalbumin murine model of vaccination.ImmunoHorizons · 2025Article
- A novel nanoparticle vaccine displaying multistage tuberculosis antigens confers protection in mice infected with H37Rv.NPJ vaccines · 2025Article
- Article
- Evaluating the immunogenicity and safety of ID93 + GLA-SE in BCG-vaccinated healthy adults: a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.Biomaterials · 2023Article
- Formulated Phospholipids as Non-Canonical TLR4 Agonists.Pharmaceutics · 2022Article
- The role of dendritic cells in the immunomodulation to implanted biomaterials.International journal of oral science · 2022Review
- Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.Current opinion in virology · 2022Review
- MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.Frontiers in immunology · 2022Article
- Inflammasome Contribution to the Activation of Th1, Th2, and Th17 Immune Responses.Frontiers in microbiology · 2022Review
- Review
- Review
- TBK1 and IKKε act like an OFF switch to limit NLRP3 inflammasome pathway activation.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- NLRP3 inflammasome activation and cell death.Cellular & molecular immunology · 2021Review
- Pharmacological Activities forFoods (Basel, Switzerland) · 2021Review
- Inflammasomes and adaptive immune responses.Nature immunology · 2021Review
- Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.International journal of molecular sciences · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The involvement of innate receptors that recognize pathogen- and danger-associated molecular patterns is critical to programming an effective adaptive immune response to vaccination. The synthetic TLR4 agonist glucopyranosyl lipid adjuvant (GLA) synergizes with the squalene oil-in-water emulsion (SE) formulation to induce strong adaptive responses. Although TLR4 signaling through MyD88 and TIR domain-containing adapter inducing IFN-β are essential for GLA-SE activity, the mechanisms underlying the synergistic activity of GLA and SE are not fully understood. In this article, we demonstrate that the inflammasome activation and the subsequent release of IL-1β are central effectors of the action of GLA-SE, as infiltration of innate cells into the draining lymph nodes and production of IFN-γ are reduced in ASC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.